{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:11:43Z","timestamp":1791173503556,"version":"4.1.0"},"reference-count":9,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestion"],"published-print":{"date-parts":[[2002]]},"abstract":"<i>Background:<\/i> A modification of the intestinal flora and an increased bacterial translocation is a common finding in patients with inflammatory bowel disease as well as in animal model of colitis. Rifaximin, a non-absorbable derivative of rifamycin, is an effective antibiotic that acts by inhibiting bacterial ribonucleic acid synthesis. <i>Aims:<\/i> In the present study, we investigated the effect of the administration of rifaximin (10, 30 and 50 mg\/kg\/day) or prednisolone (10 mg\/kg\/day) in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. <i>Methods:<\/i> Colitis was induced in mice by intrarectal administration of TNBS (1.5 mg\/mouse in 50% ethanol) and disease severity assessed clinically and by histologic scoring of colon damage, determination of interleukin (IL)-2, IL-12, interferon (IFN)-\u03b3 and tumor necrosis factor (TNF)-\u03b1 (protein and mRNA and myeloperoxidase (MPO) activity in the colon. Cytokines production by the lamina propria mononuclear cells (LPMC) and luminal bacteria were also measured. <i>Results:<\/i> Rifaximin administration (30 or 50 mg\/kg\/day) increased survival rates of colitic mice and reduced colitis severity as demonstrated by improvement of wasting syndrome, histologic scores, decrease in colon IL-2, IL-12, IFN-\u03b3 and TNF-\u03b1 (protein and mRNA) levels, and diminished colon MPO activity. Rifaximin administration caused a significant reduction of colon bacterial translocation towards mesenteric lymph nodes. LPMC obtained from rifaximin-treated mice released significantly lower amount of IFN-\u03b3 in response to ex vivo stimulation with agonistic anti-CD3 and anti-CD28 antibodies. Rifaximin (50 mg\/kg\/day) significantly accelerates recovery in mice with established colitis. <i>Conclusions:<\/i> Luminal bacterial microflora plays a role in the pathogenesis of TNBS-induced colitis in mice. Rifaximin administration reduces the development of colitis and accelerates healing of established disease by preventing bacterial translocation.<\/jats:p>","DOI":"10.1159\/000068362","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T21:05:40Z","timestamp":1050440740000},"page":"246-256","source":"Crossref","is-referenced-by-count":88,"title":["Inhibition of Intestinal Bacterial Translocation with Rifaximin Modulates Lamina propria Monocytic Cells Reactivity and Protects against Inflammation in a Rodent Model of Colitis"],"prefix":"10.1159","volume":"66","author":[{"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mencarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Barbanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Palazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2003,2,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-2494(98)80151-X"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.6.855"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/39614"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.8.1169"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.5.1281"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.241377298"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.1.25"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01000-1"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1681.2001.03388.x"}],"container-title":["Digestion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/68362","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/68362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:33:14Z","timestamp":1745465594000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000068362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2002,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000068362","archive":["Portico"],"relation":{},"ISSN":["0012-2823","1421-9867"],"issn-type":[{"value":"0012-2823","type":"print"},{"value":"1421-9867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002]]}}}